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PURPOSE. To characterize the spectrum of mutations in the
OPA1 gene in a large international panel of patients with
autosomal dominant optic atrophy (adOA), to improve under-
standing of the range of functional deficits attributable to
sequence variants in this gene, and to assess any genotype–
phenotype correlations.
METHODS. All 28 coding exons of OPA1, intron–exon splice
sites, 273 bp 5 to exon 1, and two intronic regions with
putative function were screened in 94 apparently unrelated
white patients of European origin with adOA by single-strand
conformational polymorphism (SSCP)–heteroduplex analysis
and direct sequencing. Clinical data were collated, and putative
mutations were tested for segregation in the respective families
by SSCP analysis or direct sequencing and in 100 control
chromosomes. Further characterization of selected splice site
mutations was performed by RT-PCR of patient leukocyte RNA.
Staining of mitochondria in leukocytes of patients and control
subjects was undertaken to assess gross differences in mor-
phology and cellular distribution.
RESULTS. Twenty different mutations were detected, of which
14 were novel disease mutations (missense, nonsense, dele-
tion-frameshift, and splice site alterations) and six were known
mutations. Mutations were found in 44 (47%) of the 94 families
included in the study. Ten new polymorphisms in the OPA1
gene were also identified. Mutations occur throughout the gene,
with three clusters emerging: in the mitochondrial leader, in
the highly conserved guanosine triphosphate (GTP)-binding
domain, and in the COOH terminus. Examination of leuko-
cyte mitochondria from two unrelated patients with splice site
mutations in OPA1 revealed no abnormalities of morphology
or cellular distribution when compared with control individuals.
CONCLUSIONS. This study describes 14 novel mutations in the
OPA1 gene in patients with adOA, bringing the total number so
far reported to 54. It is likely that many cases of adOA are due
to mutations outside the coding region of OPA1 or to large-
scale rearrangements. Evaluation of the mutation spectrum
indicates more than one pathophysiological mechanism for
adOA. Preliminary data suggests that phenotype-genotype cor-
relation is complex, implying a role for other genetic modify-
ing or environmental factors. No evidence was found of patho-
logic changes in leukocyte mitochondria of patients with
adOA. (Invest Ophthalmol Vis Sci. 2002;43:1715–1724)
Autosomal dominant optic atrophy (adOA) is the common-est hereditary optic neuropathy with an estimated disease
prevalence of between 1 in 10,0001 and 1 in 50,000.2 Key
clinical features of the disorder are progressive loss of visual
acuity, beginning in the first two decades of life, color vision
disturbances, paracentral scotomas and bilateral temporal atro-
phy of the optic nerve.3,4 Histologic examination of donor eyes
suggests that the fundamental pathologic characteristic of
adOA is primary degeneration of retinal ganglion cells followed
by ascending atrophy of the optic nerve.5,6 The disease dis-
plays great variability in phenotypic expression, both between
and within families.7 The disease was originally reported to
show penetrance of greater than 90%,8,9 but more recent
studies suggest that the penetrance may in fact be as low as
43%.10 Although one adOA pedigree has been reported that
maps to chromosome 18q12.2-12.3 (OPA4),11 the predomi-
nant genetic locus for this disorder (OPA1: Mendelian Inheri-
tance in Man [MIM] 165500) has been mapped to a 1.4-cM
interval on chromosome 3q28-q29.12,13
The OPA1 gene has been identified recently from within
this interval and has been shown to harbor mutations in pa-
tients with adOA.14,15 The OPA1 mRNA (GenBank accession
AB011139; GenBank is provided in the public domain by the
National Center for Biotechnology Information [NCBI], Be-
thesda, MD, and is available at http://www.ncbi.nlm.nih.gov/
genbank/) is 5821 bp long and is split into 29 exons spanning
more than 60 kb of genomic DNA. The first 28 exons of the
gene encode a dynamin-related large guanosine triphosphatase
(GTPase) of 960 amino acids.14,15 Although the cellular role of
OPA1 is unknown, putative functional information has been
derived from in silico analysis of the primary protein sequence,
which reveals a mitochondrial import motif also observed in
dynamin-related large GTPases from other species that are
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most likely orthologues of OPA1.14,15 Studies in yeast have
demonstrated that Dnm1,16 Mgm1,17 and Msp118 play an im-
portant role in the dynamics of mitochondrial morphology and
the fusion–fission processes that occur continually throughout
the life of a cell. Of the yeast proteins, OPA1 shows greatest
similarity (31%–33% over 236 amino acids [aa]) at the primary
level to Mgm1 (Saccharomyces cerevisiae) and Msp1 (Schizo-
saccharomyces pombe), the precise functions of which are
unknown.18 It is likely that OPA1 is involved in a similar
mitochondrial fusion–fission pathway in humans.
Previous studies have reported a variety of mutations in
OPA1 associated with adOA, including missense, nonsense,
insertions, deletions, and splicing mutations.10,14,15,19 These
mutations are spread throughout the gene coding sequence,
with most of them clustering over the cDNA region corre-
sponding to the GTPase domain (exons 8–16) and the 3 end
of the coding region (exons 27–28), whereas there is a relative
paucity of mutations in exons 1 to 7.10,19
In this study, we screened, by SSCP or heteroduplex anal-
ysis, a large cohort (n  94) of apparently unrelated patients
with adOA for mutations in OPA1. In addition to the coding
exons and associated splice sites, we also screened 273 bp 5
to the start of OPA1 exon 1, and 2 intronic regions (in introns
5 and 27) that were predicted by in silico sequence analysis to
contain putative exons. We report 14 novel adOA mutations in
OPA1, including five in hitherto unaffected exons (2, 3, 7, 18)
and describe 10 new polymorphic variants. We established the
molecular consequence at the RNA level of different splicing
mutations in two unrelated patients. Furthermore, we per-
formed mitochondrial staining on isolated leukocytes of se-
lected affected individuals to investigate any gross differences
in morphology or cellular distribution of these organelles.
MATERIALS AND METHODS
Patients, Families, and Samples
Ninety-four white, apparently unrelated patients and families of Euro-
pean origin (UK, n  51; Denmark, n  36; Belgium, n  2; Sweden,
n  1; Brazil, n  2; Switzerland, n  2) were recruited in different
clinical centers. This study conformed to the tenets of the Declaration
of Helsinki, and informed consent was obtained from the subjects after
an explanation of the purpose of the study. Diagnosis of adOA was
based on the presence of typical clinical features ascertained by clinical
ophthalmic tests, including visual acuity, color vision, visual fields,
electrophysiology, and optic disc appearance.4,7 Blood samples were
taken and genomic DNA extracted with a kit (Nucleon II; Scotlab
Bioscience; Strathclyde, Scotland, UK). Ninety patients were from
pedigrees with affected members in at least two subsequent genera-
tions, and four were from families with multiple affected siblings only.
Thirty-seven of the families had undergone prior marker analysis and
had linkage–haplotype data compatible with the disease’s mapping to
the OPA1 locus on 3q28.
Mutation Screening
All 28 coding exons of OPA1 and intron–exon splice sites were
screened for mutations by SSCP, heteroduplex analysis, and direct
sequencing in one affected individual from each family. Putative mu-
tations were tested for segregation in the respective families by single-
strand conformational polymorphism (SSCP)–heteroduplex analysis or
direct sequencing and in 100 control chromosomes. PCR products
were amplified from patient’s DNA using primers located in flanking
intron and untranslated region (UTR) sequences.19 Standard 25-L PCR
reactions were performed for SSCP analysis, heteroduplex analysis, and
direct sequencing, using 100 to 200 ng template DNA, 50 mM KCl, 10
mM Tris (pH 8.8), 15 mM MgCl2, 1% Triton X-100, 0.2 mM each dNTP,
0.1 M each primer, and 0.2 U Taq polymerase (Bio-Line, London,
UK). Typical cycling conditions were as follows: initial denaturation of
95°C for 5 minutes; 35 cycles of 95°C for 30 seconds, 53°C to 63°C for
30 seconds (temperature optimized for each primer pair), and 72°C for
30 seconds; and a final extension of 72°C for 5 minutes.
SSCP Analysis. PCR products were labeled by incorporation of
[32P]-dCTP during amplification.20 Denatured PCR products mixed
with an equal volume of formamide loading buffer containing 40 mM
Ca(OH)2 were resolved in nondenaturing 0.5 mutation-detection
electrophoresis (MDE) gels (Flowgen, Ltd., Lichfield, UK) in 0.6
Tris-borate EDTA buffer run at 8 to 10 W for 14 to 18 hours. Autora-
diographs were exposed at 80°C for 1 to 12 hours.
Heteroduplex Analysis. PCR products were allowed to rean-
neal and then were analyzed by electrophoresis on MDE gels run at 180
V for 14 to 18 hours on commercial electrophoresis apparatus (600S;
Hoeffer Scientific Instruments, San Francisco, CA).21 Gels were stained
in 0.5 g/mL ethidium bromide and visualized on a UV transillumi-
nator.
Direct Sequencing. PCR products showing conformational
variants were sequenced bidirectionally after purification (QIAquick
PCR purification kit; Qiagen, Crawley, UK), using fluorescent
dideoxynucleotides (BigDye Terminator chemistry; PE Biosystems,
Warrington, UK) and separated on an automated sequencer (ABI 377;
PE Biosystems).
Mutation Detection in Leukocyte RNA
Leukocytes were isolated from whole blood by density-gradient cen-
trifugation (Ficoll-Paque) according to the manufacturer’s instructions
(Amersham Pharmacia Biotech, Little Chalfont, UK) and total RNA
extracted (Trizol reagent; Invitrogen Life Technologies, Groningen,
The Netherlands). Oligo(dT)-primed total leukocyte RNA was reverse
transcribed into single-stranded cDNA using Protein A Sepharose beads
(Ready-To-Go You-Prime First-Strand Beads; Amersham Pharmacia Bio-
tech) and used to amplify cDNA segments encompassing splice site
mutations IVS85g3a (cDNA PCR primers exon c6F: 5-TGTCAGA-
CAAAGAGAAAATTGAC-3, and exon c10R: 5-ATCAAACTCCCGA-
GAACTATC-3) and IVS121g3a (cDNA PCR primers exon c10F:
5-ACTCTGAGTGAAGGTCCTCAC-3, and exon c14R: 5-TCTGCCAG-
GTCTACTTTGGAC-3). RT-PCR products were separated on a 2%
low-melting-point agarose gel and reamplified after gel excision, by
using the same primers with 3 L melted template. Individual products
were then purified using the PCR purification kit (QIAquick; Qiagen)
and sequenced bidirectionally from nested primers (for IVS85g3a,
c6FN: 5-AACTTCAGGAAGAACTTCTGC-3, and c10RN: 5-AGGGCCA-
CATGGTGAGGAC-3; and for IVS121g3a, c10FN: 5-AGTTCCGG-
GAGTTTGATCTTAC-3 and c14RN: 5-AACGAATATGGTTCTCCTTCC-
3) using fluorescent dideoxynucleotide chemistry (Big Dye) and
separation on a DNA sequencer (ABI 377; PE Biosystems).
Identification of Putative Functional Sequences
within Introns of OPA1
To identify the complete OPA1 genomic sequence, BLAST analysis of
the OPA1 cDNA sequence (KIAA0567; GenBank AB011139) was per-
formed at the National Center for Biotechnology Information, NCBI
(http://www.ncbi.nlm.nih.gov/) against The Human Genome.
Genomic sequence NT_005571 was identified to contain the entire
OPA1 cDNA (identity 100%) split into its 29 exons, with only 1 gap
in intron 27, so that the entire gene (corresponding to the cDNA
sequence KIAA0567—i.e., from exon 1 to the end of exon 29) spans at
least 97 kb of genomic DNA. The intronic sequences and putative 5
UTR were subjected to NIX analysis at the Human Gene Mapping
Project (HGMP) to identify any further expressed sequence tag (EST)
matches, putative novel exons, and coding regions.22
Mitochondrial Staining of Leukocytes
Leukocytes were isolated from blood of two unrelated patients with
splice site mutations in OPA1 and two control subjects by density-
gradient centrifugation (Ficoll-Paque; Amersham Pharmacia Biotech).
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Cells were seeded onto glass coverslips in Dulbecco’s modified Eagle’s
medium, and mitochondria were visualized with mitochondrion-selec-
tive dye (MitoTracker CMXRos-H2; Molecular Probes, Eugene, OR) or
immunostained with a monoclonal antibody against subunit I of cyto-
chrome c oxidase, as described previously.23 Coverslips were mounted
onto glass slides in fluorescent glycerol-PBS solution (Citifluor; Agar
Scientific Ltd., Stansted, UK) supplemented with 1 g/mL 4,6-dia-
midino-2-phenylindole (DAPI). Slides were examined with a micro-
scope (Axiophot; Carl Zeiss, Oberkochen, Germany) equipped with
filters appropriate for rhodamine, fluorescein, and DAPI. Separate
fluorescent images were captured with a cooled, integrated camera
(ORCA; Hamamatsu, Hamamatsu City, Japan) with a 1280 1024-pixel
array and a 12-bit gray-level resolution. The images were recombined,
by using image analysis software (Photoshop; Adobe, San Diego, CA).
RESULTS
Novel OPA1 Mutations
Altogether, 20 different mutations were identified that segre-
gate with disease in families with adOA and/or are not present
in 100 control chromosomes (Table 1). We have previously
described three of the mutations unique to individual families:
1016delC, 1296delCAT, 1848del(exon 20).14 The 17 newly
identified mutations comprise three missense, two nonsense,
six splice site, and six microdeletion mutations (two in-frame,
four frameshift) spread throughout the coding portion of the
gene (Table 1). Three of these mutations have been reported
by other groups: the missense C1508A in exon 15 was recently
identified in one family10 and segregates with disease in three
of our families from the United Kingdom, the splice site change
IVS85g3a has also been previously identified in one British
family,10 and the recurrent mutation 2708del(TTAG), found in
six of our families, has been reported in 10 different families in
other studies.10,15,19
In total, 14 of the mutations are reported herein for the first
time, five of which are present in novel locations within the
gene: two in exon 2 and one each in the donor splice site of
exons 3, 7, and 18 (Table 1). An in-frame deletion in exon 2,
112-139del(18bp), detected in a Danish patient, removes six
amino acids (RSIYHS), including the first predicted cleavage
site of the mitochondrial leader sequence,14 and may therefore
affect the correct targeting of the OPA1 protein to the mito-
chondria. The two novel missense mutations (Table 1;
Leu396Arg, Arg571His) both alter conserved amino acid resi-
dues: Arg571 is conserved between orthologues in other spe-
cies,14 whereas Leu396 lies close to a GTP-binding motif in the
dynamin-related domain, is highly conserved across ortho-
logues, and is also related to human GTPases, such as dymple
and dyn2.14 One common frameshift mutation 2826delT in
exon 28, which creates a novel OPA1 COOH terminus, was
identified in 14 Danish patients (Table 1).
Testing for reduced splice site functionality in the six puta-
tive splice site mutations predicted a reduced splicing effi-
ciency to varying degrees (Table 1). Those sequence alter-
ations affecting the highly conserved consensus G at position
1 of the donor splice site IVS31g3c, IVS9del(1-5),
IVS121g3a are all predicted to completely abolish the re-
spective splice site (Table 1). RT-PCR of total leukocyte RNA
from two affected individuals from one large family segregating
the IVS121g3a mutation revealed complete skipping of
TABLE 1. Summary of Mutations in the OPA1 Gene Causing adOA Identified in This Study
DNA Change* Exon/Intron
Splice Site
Functionality† Predicted Protein
Unrelated
Patients
Country of
Origin
Linkage to
3q28‡
Missense
T1188G Exon 12 Leu396Arg 2 UK H
C1508A§ Exon 15 Thr503Lys 3 UK L
G1712A Exon 18 Arg571His 1 UK H
Nonsense
C112A Exon 2 Arg38STOP 1 UK H
A733T Exon 7 Lys245STOP 1 UK H
Splice site
IVS31g3c Intron 3 0.02  0.00 ? 1 Belgium H
IVS85g3a§ Intron 8 0.98  0.34 Minus aa 247-275 1 UK L
IVS93a3t Intron 9 1.00  0.99 ? 1 Brazil H
IVS9del(15) Intron 9 1.00  0.00 ? 1 UK L
IVS121g3a Intron 12 0.99  0.02 Minus aa 381-404 3 UK L, ND, H
IVS276t3c/ Intron 27/ 0.88  0.20 ? 1 UK H
IVS26-10c3g Intron 26 0.87  0.72 ?
Deletion
112-139del(18bp) Exon 2 del38RSIYHS 2 Denmark ND
1016delC Exon 10 Frameshift, 19 novel aa, then STOP 1 UK H
1296delCAT Exon 13 del432Ile 1 UK H
1304-1305del(GT) Exon 13 Frameshift, 8 novel aa, then STOP 1 Denmark ND
1756-1767del(12bp) Exon 18 del586RELD 1 Sweden H
2061delA Exon 21 Frameshift, 35 novel aa, then STOP 1 UK H
Deletion of entire exon Exon 20 Frameshift, 13 novel aa, then STOP 1 UK L
2708del(TTAG)§ Exon 27 Frameshift, 2 novel aa, then STOP 6
UK (5),
Brazil (1) H (5)
2826delT Exon 28 Frameshift, 22 novel aa, then STOP 14 Denmark L (5)
* Nucleotide designation beginning 1 at position 56 (translation start) of GenBank entry AB011139.
† Berkeley Drosophila genome project splice site predictor (http://www.fruitfly.org/seq_tools/splice.html).
‡ Linkage to 3q28 (L), patients from large families showing linkage to the OPA1 critical interval with Lod score 3.0; haplotype (H), patients
from families too small for linkage analysis, but whose affected members share a haplotype encompassing the OPA1 critical interval; ND, family
untyped (very few individuals).
§ Mutations also reported in independent families (Pesch et al.,19 Toomes et al.,10 and Delettre et al.15).
 Mutations have been reported previously in Alexander et al.14
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exon 12 in mature transcripts (Fig. 1). The IVS85g3a muta-
tion segregating in one family large enough to show prior
linkage to the OPA1 locus is predicted to reduce the strength
of the corresponding donor splice site, but not completely
eradicate it (Table 1). RT-PCR of total leukocyte RNA from two
disease haplotype-bearing individuals from this family, both of
whom harbor the mutation indicated skipping of exon 8 in
both cases (Fig 1), as has been reported for this mutation in an
independent study.10 This is especially interesting, because
one of these two individuals had obvious clinical signs and
symptoms of adOA, whereas the other had reduced penetrance
for the disease. Unfortunately, fresh blood could not be ob-
tained for RNA analysis from the patients with putative splicing
mutation IVS93a3t or the double alteration IVS276t3c/
IVS26-10c3g. Although these sequence alterations affect less-
conserved nucleotides, the changes segregate with adOA in the
small families in which they were detected (five affected mem-
bers and three affected members respectively), are predicted
to affect splicing efficiency (Table 1), and were not found in
more than 50 control individuals.
OPA1 Mutation Profile
This study brings the total number of adOA mutations so far
reported in OPA1 to 54 and highlights the high rate of new
mutations in this gene. Our findings enhance the adOA muta-
tion profile of OPA1 and pinpoint novel residues and domains
critical to its function (Fig. 2). We provide further evidence for
a strong clustering of missense mutations in or close to the
GTP-binding domain (exons 8–16) of OPA1, emphasizing
that OPA1 GTPase activity is particularly critical for retinal
ganglion cell development and function. The sole missense
mutation 2354A3G so far reported outside this region in
exon 23,19 together with the four in-frame deletions so far
identified in exon 2—112-139del(18bp), this study; exon 13,
1296delCAT14; exon 17, 1651delTGC19; and exon 18, 1756-
1767del(12bp), this study—are all predicted to result in a
nontruncated OPA1 polypeptide, but may lead to an altered
conformation of the protein.
Our study revealed two novel adOA mutations within the
predicted mitochondrial leader sequence (exons 1–2) of the
OPA1 gene14,15: a nonsense mutation Arg38STOP and an in-
frame deletion of six amino acids of the first of three predicted
cleavage sites for mitochondrial import peptidases.14 Examina-
tion of the putative salmon, Drosophila melanogaster, and
Caenorhabditis elegans OPA1 orthologous protein sequences
(protein accession numbers BAA32279, AAF58275, and
CAA87771, respectively) reveals only one of these sites, corre-
sponding approximately to the third in humans from amino
acid residues 100 to 110. In the murine orthologue
(AB044138), however, the first and third sites are retained
(data not shown). Future work may elucidate whether the first
cleavage site is indeed functional only in mammals.
No conserved protein motifs or domains were evident on
bioinformatic analysis of the primary sequence of the –COOH-
terminal region of OPA1, which corresponds to a third muta-
tion cluster (exons 27 and 28) and has unknown function (Fig
2). Bioinformatic analysis of the protein primary structure has
revealed two coiled–coil domains in OPA1: one spanning res-
idues 226 to 268 and one from 940 to 969.24 Coiled–coil
domains are thought to be intrinsically involved in protein
interactions and therefore highlight domains of OPA1 for fu-
ture investigation by yeast-2-hybrid/pull-down assay for bind-
ing partners. The second coiled–coil is completely removed by
the common 2708del(TTAG) mutation in exon 27 (data not
shown), but is only marginally reduced in probability score by
the 2826delT mutation in exon 28.25
Prevalence of Mutations in OPA1 in the
Current Study
Overall, OPA1 mutations were detected in 44 of 94 patients
with adOA, for a detection frequency of 47%. It is possible that
some of the remaining cases represent nonallelic genetic het-
FIGURE 1. RT-PCR amplification products from total lymphocyte RNA
of patients with adOA from two families harboring splice site muta-
tions in the OPA1 gene, G1 (IVS85g3a) and M1 (IVS121g3a).
Lanes 1 to 4: products obtained using PCR primers exon c6F and c10R;
lanes 5 to 9: products obtained using PCR primers exon c10F and
c14R. PCR templates are as follows: lane 1: Total lymphocyte cDNA
from affected individual in family G1; lane 2: total lymphocyte cDNA
from asymptomatic but mutation-carrying individual in family G1; lane
3: OPA1 gene cDNA (KIAA0567); lane 4: human control genomic DNA
(expected product size of 11.2 kb too large to amplify with Taq
polymerase); lane 5: Total lymphocyte cDNA from affected individual
in family M1; lane 6: total lymphocyte cDNA from second affected
individual in family M1; lane 7: OPA1 gene cDNA (KIAA0567); lane 8:
human control genomic DNA (no product); lane 9: human control
genomic DNA (expected amplification product of 1312 bp); lane 10:
no DNA control (primers c6F/c10R); lane 11: no DNA control (primers
c10F/c14R); lane M: size marker X174/HaeIII. Arrows: (left) sizes of
RT-PCR products from IVS85g3a–carrying cDNA (lanes 1 and 2);
(right) sizes for IVS121g3a cDNA and control genomic DNA (lanes
5, 6, 9).
FIGURE 2. Summarization of the
type and genetic location of all the
different OPA1 mutations found to
date that cause adOA. This highlights
a clustering of mutations over the
dynamin-related GTPase domain, car-
boxyl terminus, and mitochondrial
leader peptide of OPA1.
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erogeneity, autosomal recessive, or X-linked forms of optic
atrophy.25 Of the patients with mutations, 16% (7/44) were
from individual families linked to chromosome 3q28-qter with
lod scores greater than 3, and 57% (25/44) were from small
families with lod scores lower than 3 or a haplotype compati-
ble with linkage to chromosome 3q28-qter. The remaining 27%
(12/44) of the mutations were from pedigrees for which no
marker data were available, but which showed a strong family
history of optic atrophy compatible with autosomal dominant
inheritance. No mutations were discovered in families with
affected siblings in only one generation. When considering the
total number of families in each of these categories, it is
apparent that mutations are found in 70% (26/37) of pedigrees
showing linkage–haplotype data consistent with disease seg-
regation with the OPA1 locus and in only 34% (18/53) with a
family history in the absence of marker data. This finding is
important, because it suggests that it may be worth screening
a patient for a mutation in OPA1 only if haplotype–linkage data
suggest dominant inheritance of optic atrophy or if there is a
clinical picture strongly suggestive of adOA in the absence of a
clear-cut dominant history.
In addition, we identified one family of 15 affected mem-
bers that shows no evidence of linkage to the chromosome
3q28-qter OPA1 locus (D3S3669: Zmax  0.19, max  0.33;
D3S3642: Zmax  0.16, max  0.35; D3S3590: Zmax  0.97,
max  0.19; D3S3562: Zmax  0.48, max  0.50; where Z is
Lod Score and  is recombination fraction) and in which the
chromosome 18 OPA4 locus has also been excluded (data not
shown). Including only the known affected individuals from
this family in the linkage analysis excludes the chromosome
3q28 locus (D3S3669: Zmax  0.27, max  0.14; D3S3590:
Zmax  0.25, max  0.23). It is possible that this family
represents a new as yet unmapped genetic locus for adOA. The
clinical phenotype in this family is very similar to the chromo-
some 3–associated phenotype7 and also overlaps the pheno-
type of the single family mapping to the OPA4 locus on chro-
mosome 18.11
Mutation Screening of Additional ORFs in OPA1
Because mutations were not identified in 11/37 (30%) index
patients from families mapping to 3q28 through linkage–hap-
lotype analysis, we investigated the possible existence of addi-
tional as yet undetected exonic sequences or open reading
frames (ORFs) lying within the known OPA1 introns and 5
UTR, which are not present in the original full-length mRNA
sequence AB011139 (derived from brain) but may contribute
to alternative splice isoforms or tissue-specific transcripts. NIX
analysis of these OPA1 extraexonic regions predicted several
sequence segments containing putative ORFs, three of which
were examined further, in introns 5 and 27 and extending 5
from exon 1.
NIX analysis revealed 99% identity to EST BG470279 over-
lapping and extending 5 to exon 1 of OPA1 (as defined by the
start of mRNA sequence AB011139). This EST matched the
OPA1 mRNA over the mitochondrial leader (96%) and ex-
tended 5 for a further 195 bp. This region contained an ORF
in-frame with the OPA1 protein sequence (BAA29453), poten-
tially adding a further 63 amino acids to the 5 of OPA1 or,
alternatively, containing regulatory sequences. However, we
discovered no SSCP band shifts on screening 273 bp 5 to
OPA1 exon 1 in adOA index patients.
A 111-bp stretch of DNA in intron 5 (IVS57613-7724)
gave an excellent exon prediction by three different programs
(GRAIL, GENSCAN, and Genefinder22), with predicted splice
sites matching the Kozak consensus26 and a predicted ORF of
37 amino acids. Although this polypeptide sequence showed
no significant match by BLAST analysis to any known pro-
tein sequence, the predicted exon (putative exon 5a) iden-
tified two human ESTs (99% identity; AA334558, embryo;
AW996319, breast) which both contained contiguous se-
quence 3 and 5 to the region of identity matching exons 5
and 6 of the OPA1 gene (AB011139). The putative exon also
identified four mouse ESTs by sequence similarity search
(BB254844, 89%, cerebellum; BB395916, 90%, cerebellum;
BB546811, 93%, eye; BE303971, 96%, ductal carcinoma),
which show 92% to 98% identity to mouse mRNA for large
GTP-binding protein AB044138, the presumed murine ortho-
logue of human OPA1 (88% identity over the entire length at
the nucleotide level, 96% at the amino acid level). This may be
indicative of conserved, hence functionally important, sequences.
NIX analysis of intron 27 predicted a marginal exon (FEX,
HEXON, FGENE22) spanning a 365-bp stretch of DNA
(IVS271041-1406; putative exon 27a). Putative acceptor
and donor splice sites were present (scores 0.97 and 0.89
respectively; http://www.fruitfly.org/seq_tools/splice.html).
This predicted exon translates into an ORF of 121 amino acids,
showing no significant similarity to known polypeptides. How-
ever, this nucleotide stretch shows 100% identity to an EST
(accession T96104) and to UniGene cDNA cluster Hs.331315
(complementary strand). There is also a polyadenylation signal
205 bp downstream of this predicted exon, which could rep-
resent the 3 end of an alternative OPA1 transcript.
RT-PCR of fetal brain cDNA (Stratagene, La Jolla, CA), adult
retina cDNA library lysates (gift from Jeremy Nathans, Johns
Hopkins Medical School, Baltimore, MD), and normal leuko-
cyte cDNA (prepared as above from control blood) using cDNA
primers designed to amplify from exon 5a to exon 7, and exon
26 to exon 27a, produced no amplification product. This sug-
gests that these putative exons are not present in contiguity
with exon 7 (for 5a) or exon 26 (for 27a) in the library aliquots
studied. Furthermore, SSCP analysis of patients with adOA, in
whom no OPA1 mutation had been identified, revealed no
sequence alterations in putative exons 5a or 27a.
Current Single-Nucleotide Polymorphism Catalog
of OPA1
During the mutation screening, 16 single-nucleotide polymor-
phism SNPs were found within the OPA1 gene, 10 of which are
reported herein for the first time (Table 2). Two of these
sequence changes, C500T and IVS7del(49-51), were identi-
fied in single adOA families and were not found in 100 control
chromosomes. That C500T, although resulting in the noncon-
servative amino acid change Pro167Leu, clearly did not segre-
gate with disease in the family in which it was detected on
repeated analysis makes it likely to be a rare polymorphism.
This amino acid substitution is a known polymorphic variant in
other genes.27,28 The IVS7del(49-51) alteration was found in
a patient who also harbored the 2708del(TTAG) frameshift
mutation (Table 1). This work extends the current SNP catalog
for OPA1 to 27, of which 9 are cSNPs.10,15,19
Morphology and Cellular Distribution of
Mitochondria in Leukocytes of Patients and
Control Subjects
To investigate whether OPA1 mutations had an effect on mor-
phology and cellular distribution of mitochondria, we stained
mitochondria of leukocytes from two unrelated patients (har-
boring mutation IVS121g3a and IVS85g3a) and normal
individuals with mitochondrion-selective dye (MitoTracker
CMXRos-H2; Molecular Probes). The dye showed that mito-
chondria were present as discrete entities in the cytosol
around the nucleus of these circulating cells (Fig. 3). There was
no notable difference in mitochondrial morphology and distri-
bution between patients and control subjects. Immunostaining
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with a monoclonal antibody against the mitochondrial DNA-
encoded subunit I of cytochrome c oxidase produced an iden-
tical staining pattern (data not shown).
Clinical Features of Pedigrees with adOA
OPA1 Mutations
Clinical data for 11 families in the United Kingdom with OPA1
mutations in whom affected and unaffected members were
examined are summarized in Table 3. There was widespread
intra- and interfamily variability in the phenotype. Seven of 11
families had at least one individual with clinical onset of disease
before the age of 6 years. Conversely, the clinical diagnosis was
made in individuals in four families as late as their third (fam-
ilies A1, K1, T1; Table 3) or fifth (family G1) decade. Visual
acuity and disc appearances showed no notable association
with type or intragenic location of mutations. Visual acuity
ranged from 6/9 to hand-movement perception, and disc ap-
pearances ranged from subtle atrophy to total pallor. Compar-
ing the clinical data for different families segregating the same
mutation—for example, B1 and L1 (C1508A, predicting the
Thr503Lys substitution) and B3 and C7 (2708del(TTAG), pre-
dicting a frameshift deletion at codon 902)—it does appear
that these families share more similarities in clinical symptom
severity than families with other mutations. This is especially
true for the C1508A mutation where several affected members
were examined from each family (Table 3). This may in part be
due to the shared genetic context of the disease allele in the
families with the C1508A mutation, who display a common
disease haplotype at the OPA1 locus (data not shown). This
suggests that these families may have common ancestors, con-
sistent with their broadly similar clinical profile (Table 3), and
also that genetic background may be a key factor influencing
the clinical variability in expression of individual mutations.
Patients with mutations in the latter sections of the gene—for
example, exon 27: 2708del(TTAG) or splice IVS276t3c/
IVS26-10c3g—do not have a milder phenotype than patients
with mutations predicted to severely truncate the protein (Ta-
ble 3).
Mutations in Families with Reduced Penetrance
Penetrance is not clearly defined in the literature and is used in
different ways by different investigators. A fully penetrant in-
dividual shows symptoms and signs of the disease and carries
a disease-associated mutation. We have defined nonpenetrance
in an individual patient as the detection of a disease-associated
mutation in an individual who shows no symptoms or clinical
signs of the disease on examination. Partial penetrance is taken
as meaning an individual who is asymptomatic but has a func-
TABLE 2. Polymorphic Variants Found in the OPA1 Gene in This Study
DNA Change Consequence Location
Unrelated OA
Patients
(n)
Control Allele
Frequency
(%) Comment
Restriction Enzyme
Assay
Exonic
A473G* Asn158Ser Exon 4 5 A/53 G/47 CjeI site
C500T Pro167Leu Exon 4 1 C/100 T/0 No familial segregation BfaI site
C580T* Ala192Val Exon 5 2 C/98 T/2 MwoI site
A1609C* Ala536Ala Exon 17 5 A/94 C/6 HaeIII site
C2109T* Ala703Ala Exon 21 5 ND HaeIII site
Intronic
IVS7del(4951) gttgtgt3gt–gtg Intron 7 1 0 AflIII site
IVS832c3t* caatta3caacta Intron 8 5 ND BfaI site
IVS1018a3g tctaag3tctgag Intron 10 4 ND MnlI site
IVS1332a3g actgat3actggt Intron 13 2 A/99 G/1
Creates splice site 0.91 putative
splice enhancer† BsrI site
IVS1816t3g actcgt3acgcgt Intron 18 5 T/96 G/2 MluI site
IVS1851t3g gtttgc3gtgtgc Intron 18 5 T/50 G/50 TthIII11 site
IVS25–142t3c tatatc3tacatc Intron 25 5 ND No change
IVS25–112a3g tgagta3tgggta Intron 25 5 ND ScaI site
IVS2626t3a* ttattt3taattt Intron 26 5 ND Sse91 site
IVS2723t3c tctacc3tccacc Intron 27 1 ND No splice site created No change
IVS27108g3a cacggt3cacagt Intron 27 2 G/97 A/3 BsrI site
ND, not determined.
* Previously reported in Pesch et al.,19 Toomes et al.,10 and Delettre et al.15
† Correct donor site 1.00.
FIGURE 3. Mitochondrial distribution in leukocytes. Monocytes and
neutrophils of a normal individual and a patient were stained with a
mitochondrion-selective dye (red). Cells were counterstained with
DAPI to reveal the nucleus (blue). No difference in mitochondrial
distribution was observed between patients and control subjects.
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tional deficit evident in clinical examination, albeit very mild.
The person may be subclinically affected, requiring more so-
phisticated tests, such as perimetry, to make the diagnosis of
affected status.29 It is clearly difficult to draw the boundaries
between reduced (or partial) penetrance and expressivity, and,
indeed, variable expressivity may be a reflection of reduced
penetrance.
Based on these definitions, an estimate of penetrance for
the two families in whom it was possible to examine all
affected and unaffected individuals showed highly differing
values ranging from 100% (pedigree A1, splice site mutation
intron 12: IVS121g3a) to 67% (pedigree K1, deletion of
entire exon 20). From the 11 pedigrees in Table 3, we detected
four cases of nonpenetrance in three pedigrees (K1, L1, and
P1) after clinical examination of symptomatic and asymptom-
atic family members.
We found six further individuals in five adOA-affected ped-
igrees (not tabulated in Table 3) who were asymptomatic and
who carried the disease-associated mutation, but for whom
clinical data are insufficient to make the distinction between
nonpenetrance and partial penetrance on these criteria: one
patient: exon 18, G1712A; one patient: exon 18, 1756-1767del;
three patients from two families: exon 27, 2708del(TTAG); and
one patient: exon 28 (2826delT). The mutation exon 27
2708del(TTAG) has been associated with reduced pen-
etrance.10 However, the presence of reduced penetrance in
family P1 with mutation IVS9del(1-5) suggests that a predis-
position to reduced penetrance is not solely due to mutations
located 3 to the GTPase domain of OPA1.
DISCUSSION
Current Spectrum of OPA1 Gene Mutations:
A Key Role for the Carboxyl Terminus?
An increasing range of mutations in the OPA1 gene are being
identified in families with adOA.10,19 In this study we identified
14 novel OPA1 mutations in an independent cohort of 94
patients or pedigrees with adOA, 37 of which showed prior
linkage–haplotype evidence consistent with a map location
including the OPA1 interval. We also addressed the possibility
that clinical symptoms of the disease may be the result of
altered mitochondrial integrity or subcellular localization. We
also examined our clinical data for any evidence of genotype–
phenotype correlation and made attempts to address the ob-
served low detection rate of OPA1 mutations in patients with
adOA.
Of the 54 OPA1 mutations reported to cause adOA to date,
the majority (26, or almost 50%) cause premature truncation of
the OPA1 protein or create novel –COOH termini. This number
may in fact be larger, owing to the introduction of frameshifts
by some of the 11 splice site mutations, which has not yet been
demonstrated because patients’ RNA was unavailable (Table
1).10,19 Recent studies have shown that some missense and
nonsense mutations, previously presumed to exert their patho-
genic effects solely on either the resultant amino acid change
or protein truncation, may instead lead to aberrant splicing by
disruption of exon-splicing enhancers (ESEs) or suppressors
(ESSs).30 Whether this means that most cases of adOA caused
by mutations in OPA1 effectively result from null mutations
that may halve the amount of normal OPA1 protein in the cell
(haploinsufficiency) and this is sufficient to cause disease
awaits the results of future experiments. Many mutations do
not truncate the protein, which may either be rapidly degraded
or interfere in a dominant–negative manner with the OPA1
polypeptide arising from the normal gene copy. Therefore,
there is possible evidence for more than one disease mecha-
nism underlying adOA.TA
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The cluster of mutations resulting in loss or abnormality of
the COOH terminus of OPA1 highlights the physiological
importance of this protein domain. The occurrence of a
founder mutation—exon 28, (2826delT)—in the COOH ter-
minus may account for the high frequency of adOA in Den-
mark.24 That adOA mutations in the 3 coding exons 27 and 28
which disrupt the ORF can produce a phenotype of clinical
severity comparable to those in regions of known functional
significance highlights the integral contribution of the OPA1
–COOH terminus to the correct cellular function of this pro-
tein. The –COOH terminus of the dynamin family of GTPases is
not well conserved, apparently imparting unique functional
attributes to each specific member, and it may be that this
region of OPA1 is intrinsically essential to its specific role in the
mitochondria.31 This may explain how mutations affecting
only the very –COOH end of OPA1 protein could give rise to
disease.
Low Detection Rate of OPA1 Gene Mutations in
adOA Pedigrees
In total, SSCP and heteroduplex analysis of all coding exons of
OPA1 identified mutations in 44 of 94 adOA patients, an overall
detection rate of 47%. This is comparable with the results of
other recent studies with rates ranging from 32.1% to 57%.10,19
This low detection rate may be ascribed to a combination of
factors: the screening methods used are not 100% effective (in
our case, SSCP–heteroduplex analysis); large-scale mutations
(deletions, insertions) are undetectable by these same meth-
ods, which may account for a significant number of cases; or
mutations residing in unscreened portions of the gene (e.g.,
introns, 5 UTR–promoter regions, 3 UTR). However, the
mutation detection methods we used are known to be at least
80% effective,32 which alone would not account for the 53% of
mutations left undetected. If there are OPA1 mutations present
in the remaining patients, it is likely that they reside in non-
coding portions of the gene involved in regulatory processes or
nondetection may be due to gross DNA rearrangements that
require other methods (e.g., Southern blot analysis, RT-PCR)
for their detection.
The OPA1 gene has been shown to express alternative
transcripts in a variety of tissues.14,15 To address the possibility
that additional exons and ORFs exist in the introns or 5 or 3
UTRs of the original brain-derived transcript (GenBank entry
AB011139), we extracted these sequences through computa-
tional analysis from The Human Genome at NCBI and sub-
jected them to NIX analysis in the HGMP.22 Introns 5 and 27
contained exons predicted by more than one program, with
ORFs and EST matches. Although we did not find any adOA
mutations in these putative exons and could not link them to
the known OPA1 transcript sequence in human retina, fetal
brain cDNA libraries or leukocyte cDNA, further studies may
reveal functional significance for these OPA1-intragenic se-
quences and others like them. Even if such intronic sequences
do not normally contribute to the OPA1 transcript profile,
pseudoexon activation, caused by mutations in intronic nucle-
otides, is becoming more widely recognized as a genetic dis-
ease mechanism.33 Screening of 273 nucleotides, matching
EST BG470279 and extending the ORF 5 to the putative start
of OPA1 exon 1, revealed no further mutations in our panel of
patients.
Mitochondrial Integrity and Subcellular
Localization in Lymphocytes of Patients and
Control Subjects
The pathophysiology and clinical symptoms observed in adOA
show overlap with those occurring in Leber hereditary optic
neuropathy,34 caused by mutations in mtDNA-encoded genes
for subunits of complex I of the respiratory chain.35 Therefore,
it is tempting to speculate that mutations in OPA1 leading to
disturbances of mitochondrial integrity may compromise the
energy supply to the highly energy-demanding optic nerve
tissue, so that it degenerates and visual impairment ensues.
Delettre et al.15 reported that the mitochondrial network is
disorganized in leukocytes from patients with OPA1. Their
micrograph of control leukocytes immunostained with anti-
HSP60 showed general cytoplasmic staining with no evidence
of a mitochondrial network, whereas the antibody seemed to
reveal clumps of mitochondria in patients’ cells. Our results are
very different. Instead of a general cytoplasmic staining of
control leukocytes, we clearly observed a discrete mitochon-
drial network in the cytosol with the mitochondrion-selective
dye (Fig. 3) and with an antibody against cytochrome c oxidase
subunit I (data not shown). Patients’ cells showed a mitochon-
drial network that was indistinguishable from that of normal
individuals and, moreover, similar to the results reported by
Delettre et al.15 Blood monocytes and granulocytes have extra-
large nuclei, folded and lobed, respectively, that leave little
room for the cytoplasm in these cells. We thus believe that the
distribution of mitochondria observed in patients by both
groups, actually represents the typical pattern expected for
normal blood monocytes. Therefore, we conclude that these
OPA1 mutations have no observable effect on the mitochon-
drial distribution in leukocytes. The contradictory results of
Delettre et al.15 could in part be explained by the fact that
different patients and mutations were studied but are more
likely due to differences in methodology. The absence of any
mitochondrial network in their control cells suggests that the
cellular structures were not properly fixed before antibody
incubation. If adOA caused by OPA1 mutations is a mitochon-
driopathy, our findings failed to provide evidence that the
disease is readily observable in patients’ leukocytes. Either the
mitochondrial abnormalities are limited to the cells of the
retinal ganglion cell layer or optic nerve or are more subtle
than our methods can detect. Systematic characterization of
mitochondria staining patterns across a more comprehensive
array of patient OPA1 mutations and control individuals is
warranted to clarify this issue. Nevertheless, we conclude that
diagnosis of adOA based on mitochondrial morphology or
distribution in blood leukocytes is currently inadvisable.
OPA1 Gene Founder Effects and Mutation Hot
Spots in adOA
One frameshift mutation 2826delT in exon 28 has been iden-
tified in 14 Danish patients (Table 1). Statistical analysis of
patient haplotypes versus control subjects strongly indicates
this mutation to be a founder allele in the Danish population,
which may explain the higher prevalence of adOA in Den-
mark.24
Of 38 British families previously analyzed by haplotype and
linkage disequilibrium analysis, 36 had haplotypes compatible
with a founder effect.36 We have found mutations in 15 of
these families. The gene OPA1 lies closest to marker D3S2305,
contrary to the predicted likely position by linkage disequilib-
rium, which placed the gene at approximately 400 kb either
side of D3S1523. The inaccuracy of the founder prediction may
be in part due to a change in marker order used in the founder
prediction versus the marker order now accepted through
physical mapping.24 Marker D3S2305, then placed between
D3S3642 and D3S3590, using the best available genetic data
then available (GeneMap 1997 [http://www.ncbi.nlm.nih.gov/
genemap97]), is now known to lie between D3S3590 and
D3S3562. This change in marker order over a critical part of
the haplotype has the effect of breaking up the core founder
haplotype so that only 15 families appear to share a core
haplotype across the OPA1 disease interval.
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Examination of our revised marker allele data for microsat-
ellite markers spanning the D3S3669-D3S3562 interval reveals
that three families with a mutation in exon 15 (C1508A, two of
which are B1 and L1 in Table 3) share a common haplotype for
markers D3S3642, D3S3590, and D3S3562, encompassing a
640kb genomic interval (data not shown). Of the 12 remain-
ing families in whom we have found mutations and who were
analyzed in the assessment of the founder effect,36 only three
others show a core haplotype from markers D3S1523 to
D3S2305 that would be consistent with a founder effect. How-
ever, these three families have three different splice site mu-
tations: IVS85g3a (family G1), IVS121g3a (family A1),
and IVS276t3c/-10c3g (family F3), illustrating that a com-
mon haplotype does not always guarantee common ancestry.
The 2708del(TTAG) frameshift mutation has been found in
white patients of various nationalities (Australian, France, Bel-
gian, German, British, Brazilian; Table 1),10,15,19 which may
indicate that it represents a mutation hot spot. Two novel
recurrent mutations detected in this screen are located in exon
12: missense T1188G in two British families and splice site
IVS121g3a in three British families (Table 1). We found no
evidence of shared haplotypes for OPA1-linked markers in
these families, implying novel mutation hot spots in this gene.
Intra- and Interfamily Variability in Expression
of adOA
Preliminary data suggest that phenotype–genotype correla-
tions in patients with adOA with mutations in the OPA1 gene
appear to be weak and indicate that other factors, such as
genetic background, modifier loci, and/or environmental influ-
ences play an important role in phenotypic expression. There
was a fairly frequent occurrence of asymptomatic carriers in
our family cohort with mutations, notably in two families with
the 2708del(TTAG) mutation, as has been reported previ-
ously.10 Furthermore, we found cases of nonpenetrance in
families with three other mutations, with a variable penetrance
estimate in appropriate large families from 100% for the
IVS121g3t mutation, resulting in exon 12 skipping, to 67%
for the del(exon20) frameshift mutation. Thus it appears that
adOA may be a monogenic disorder due primarily to the
disruption of a single gene, but has a complex phenotypic
expression owing to other genetic, epigenetic or environmen-
tal factors impacting greatly on the clinical outcome.37
There are now 27 polymorphisms described within exons
and introns of the OPA1 gene, including 10 that are novel in
this study. Sequence variants, such as these, although not
individually associated with adOA, may contribute to subtle
variations in structure and function, or may influence gene
expression and the phenotypic expression of individual muta-
tions. Variable penetrance in genetic disease has been shown
in some instances to be affected by polymorphisms within the
wild-type allele at the disease locus.38 Although we do not yet
know the mechanism of reduced penetrance in adOA caused
by mutations in the OPA1 gene, a catalog of benign sequence
variants will undoubtedly add to our future understanding of
how this gene and its encoded protein operate in health and
disease.
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